Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infectious bacterial or fungal keratitis with : size \> 2mm or within the central corneal area ( 3mm of the visual axis ) or with a reaction in anterior chamber.~* Being major responsible.~* Agreement in writing to participate in the study.~* Being affiliated to a national insurance scheme.~Exclusion Criteria:~* Present an infectious keratitis without all the previous criteria.~* Herpes or acanthamoeba keratitis~* preperforated or perforated cornea.~General criteria:~* Pregnant woman.~* Minors(miners).~* Adults under guardianship.~* Patient can not be followed during 3 necessary months.~* French speaking patient.~* Unaffiliated patient in a national insurance scheme.~* HIV infected patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- antibiotic treatment alone (Type: ACTIVE_COMPARATOR): None
- Crosslinking + Antibiotic (Type: EXPERIMENTAL): The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation.

Based on this trial design, predict the completion outcome and termination type (if applicable).